Nephrotic Syndrome Treatment Market Size in the 7MM was ~USD 401 Million in 2022, is expected to increase by 2034 | DelveInsight

DelveInsight's "Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology, and the Nephrotic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Nephrotic Syndrome Market with DelveInsight's In-Depth Report @ Nephrotic Syndrome Market Size [https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Nephrotic Syndrome Market Report

* As per DelveInsight's estimations, the total Nephrotic Syndrome diagnosed prevalent cases in the 7MM were approximately 786k in 2022 and are projected to increase during the forecast period.
* The overall count of individuals diagnosed with Nephrotic Syndrome in the United States was approximately 268k in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
* Among the 7MM, the US accounted for nearly 214k cases of Primary Glomerulonephropathies, and 54k cases of Secondary Glomerulonephropathies. These cases are expected to increase during the forecast period (2023-2034).
* Among EU4 and the UK, Germany had the highest Nephrotic Syndrome diagnosed prevalent population, with about 98k cases, followed by the UK and France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
* In Japan, there were around 151k Nephrotic Syndrome diagnosed prevalent cases in 2022. These cases are expected to decrease by 2032.The leading Nephrotic Syndrome Companies such as GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB , and others.
* Promising Nephrotic Syndrome Pipeline Therapies such as Mizoribine (MZR), Cyclophosphamide (CTX), Obinutuzumab, Prednisone, Tacrolimus , and others.

Discover which therapies are expected to grab the Nephrotic Syndrome Market Share @ Nephrotic Syndrome Market Outlook [https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Nephrotic Syndrome Epidemiology Segmentation in the 7MM

- Total Nephrotic Syndrome Diagnosed Prevalent Cases

- Nephrotic Syndrome Type-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Nephrotic Syndrome Epidemiology trends @ Nephrotic Syndrome Prevalence [https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Nephrotic Syndrome Emerging Drugs

* Atacicept: Vera Therapeutics

Atacicept developed by Vera Therapeutics, is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgA nephropathy and lupus nephritis.

* Atrasentan: Chinook Therapeutics/ Novartis

Atrasentan is an oral potent and selective endothelin A (ETA) receptor antagonist, which works by inhibiting the ETA receptor activation of multiple renal cell types. This blockade reduces kidney inflammation and fibrosis, thus leading to reduced proteinuria in patients with chronic kidney disease.

Nephrotic Syndrome Market Outlook

Nephrotic syndrome is a collection of symptoms that signal impaired kidney function. These symptoms encompass proteinuria, hypoalbuminemia, edema, hyperlipidemia, and various other associated complications of Nephrotic Syndrome. The management of nephrotic syndrome entails addressing underlying medical conditions contributing to its onset. Healthcare professionals may prescribe medications and dietary modifications to regulate symptoms and address complications of nephrotic syndrome. Corticosteroids like prednisone, cyclophosphamide, and cyclosporine are employed to induce remission in nephrotic syndrome. Diuretics are utilized to alleviate edema, while angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers are employed to diminish proteinuria.

To know more about Nephrotic Syndrome treatment guidelines, visit @ Nephrotic Syndrome Treatment Market Landscape [https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Nephrotic Syndrome Companies

Vertex Pharmaceuticals, Chinook Therapeutics, Novartis, Boehringer Ingelheim, Hoffmann-La Roche, Biogen, Cerium Pharmaceuticals, Otsuka Pharmaceutical Development & Commercialization, Visterra, Ionis Pharmaceuticals, Kezar Life Sciences, Alpine Immune Sciences, Dimerix Bioscience, Advanz Pharma, Apellis Pharmaceuticals, Vera Therapeutics, Inc., AstraZeneca, HI-Bio, and others.

Scope of the Nephrotic Syndrome Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Nephrotic Syndrome Companies- GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, and others.
* Nephrotic Syndrome Pipeline Therapies- Mizoribine (MZR), Cyclophosphamide (CTX), Obinutuzumab, Prednisone, Tacrolimus, and others.
* Nephrotic Syndrome Market Dynamics: Nephrotic Syndrome Market Drivers and Barriers

Learn more about the FDA-approved drugs for Nephrotic Syndrome @ Drugs for Nephrotic Syndrome Treatment [https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Nephrotic Syndrome Market Report Introduction

3. Nephrotic Syndrome Market Overview at a Glance

4. Nephrotic Syndrome Epidemiology and Market Methodology

5. Nephrotic Syndrome Executive Summary

6. Key Events

7. Nephrotic Syndrome: Disease Background and Overview

8. Nephrotic Syndrome Epidemiology and Patient Population

9. Patient Journey

10. Nephrotic Syndrome Marketed Drugs

11. Nephrotic Syndrome Emerging Therapies

12. Nephrotic Syndrome: Seven Major Market Analysis

13. Nephrotic Syndrome KOL Views

14. Nephrotic Syndrome SWOT Analysis

15. Nephrotic Syndrome Unmet Needs

16. Nephrotic Syndrome Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nephrotic-syndrome-treatment-market-size-in-the-7mm-was-usd-401-million-in-2022-is-expected-to-increase-by-2034-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.